Clinical Scorecard: Systematic Review and Meta-Analysis of Randomized Controlled Trials on Fecal Microbiota Transplantation for Ulcerative Colitis Patients

At a Glance

Key Highlights

• Gut microbiota alterations contribute to UC pathogenesis, with decreased butyrate-producing bacteria observed in IBD patients.
• FMT aims to restore normal gut microbiota rapidly and has established efficacy in recurrent Clostridioides difficile infection.
• Efficacy of FMT in UC remains unclear and may be influenced by donor criteria, delivery route, number of sessions, and concurrent therapies.

Guideline-Based Recommendations

Diagnosis

• Diagnosis of UC should be established prior to considering FMT.
• Assessment of disease activity including clinical and endoscopic evaluation is essential.

Management

• Consider FMT as an adjunctive therapy for UC aiming for combined clinical and endoscopic remission.
• Evaluate donor selection, route of administration, and number of FMT sessions to optimize outcomes.
• Concurrent use of steroids, biologics, or other anti-inflammatory agents may affect FMT efficacy.

Monitoring & Follow-up

• Monitor patients for clinical and endoscopic remission post-FMT.
• Assess for adverse events including post-treatment worsening colitis.
• Use validated scoring systems such as the Mayo score to evaluate treatment response.

Risks

• Potential for post-treatment worsening colitis exists and should be monitored.
• Adverse events comparable to standard medical therapy have been reported.

Patient & Prescribing Data

Patients with ulcerative colitis enrolled in randomized controlled trials comparing FMT to placebo or standard treatment.

FMT may improve remission rates with a safety profile comparable to standard therapies; efficacy may vary based on patient and treatment factors.

Clinical Best Practices

• Use randomized controlled trial evidence to guide FMT use in UC patients.
• Carefully select donors and optimize FMT delivery methods.
• Incorporate FMT as part of a comprehensive treatment plan including conventional therapies.
• Perform rigorous monitoring for efficacy and adverse events post-FMT.
• Apply standardized outcome measures such as combined clinical and endoscopic remission.

References

• Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020)
• Risk of Bias-2 Tool (ROB 2)
• GRADE Approach for Certainty of Evidence